A potential coronavirus vaccine in Cuba used to treat 58 patients, including those with severe and critical conditions from COVID-19, gave promising results, according to a Cuban expert.
The CIGB 258 vaccine has an 84% survival rate, Verena Muzio, chief of the Genetic Engineering and Biotechnology Center (CIGB), told the Mesa Redonda television program Wednesday.
Muzio said 72% of critically ill patients and 90% of severe cases recovered from the virus with the vaccine treatment.
Cuba has 2,107 coronavirus cases and 83 deaths, while recoveries neared the 2,000 mark, according to the data compiled by US-based Johns Hopkins University.
Meanwhile, Brazil's Health Surveillance Agency (Anvisa) will participate in the testing phase of a vaccine developed by Oxford University, becoming "the first country where the vaccine was tried out of England," according to reports Wednesday.
The testing will involve 2,000 Brazilian patients.
Brazil is the epicenter of the pandemic in Latin America and shows a significant increase in cases and deaths while most of the world are on a downward trend. The country has more than 584,000 cases -- the second-highest count globally after the US, and more than 32,500 deaths.Anadolu Agency website contains only a portion of the news stories offered to subscribers in the AA News Broadcasting System (HAS), and in summarized form. Please contact us for subscription options.